tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

APLS Stock Latest News

Short Report: Kohls, Krispy Kreme shorts cover as meme stock fever breaks
The FlyShort Report: Kohls, Krispy Kreme shorts cover as meme stock fever breaks
1M ago
KSS
PGY
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences
PremiumRatings
Hold Rating for Apellis Pharmaceuticals’ Empaveli Amid Market Challenges and Physician Preferences
1M ago
APLS
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook
PremiumCompany Announcements
Apellis Pharmaceuticals’ Earnings Call: A Balanced Outlook
2M ago
APLS
Apellis price target raised to $37 from $35 at JPMorgan
PremiumThe Fly
Apellis price target raised to $37 from $35 at JPMorgan
2M ago
APLS
Apellis price target raised to $40 from $39 at Cantor Fitzgerald
PremiumThe Fly
Apellis price target raised to $40 from $39 at Cantor Fitzgerald
2M ago
APLS
Apellis price target lowered to $50 from $52 at Raymond James
PremiumThe FlyApellis price target lowered to $50 from $52 at Raymond James
2M ago
APLS
Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals
Premium
Ratings
Steady Growth and Future Potential: A Hold Rating for Apellis Pharmaceuticals
2M ago
APLS
Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion
Premium
Ratings
Cautious Outlook on Apellis Pharmaceuticals: Hold Rating Amidst Modest Syfovre Growth and Empaveli Expansion
2M ago
APLS
Apellis price target raised to $52 from $46 at Citi
PremiumThe Fly
Apellis price target raised to $52 from $46 at Citi
2M ago
APLS
Apellis Pharmaceuticals Reports Q2 2025 Earnings
PremiumCompany Announcements
Apellis Pharmaceuticals Reports Q2 2025 Earnings
2M ago
APLS
Apellis price target raised to $26 from $24 at Goldman Sachs
PremiumThe Fly
Apellis price target raised to $26 from $24 at Goldman Sachs
2M ago
APLS
3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts
PremiumMarket News
3 Best Stocks to Buy Now, 7/31/2025, According to Top Analysts
2M ago
GH
APLS
Apellis reports Q2 EPS (33c), consensus (47c)
PremiumThe FlyApellis reports Q2 EPS (33c), consensus (47c)
2M ago
APLS
Apellis price target raised to $22 from $20 at Scotiabank
Premium
The Fly
Apellis price target raised to $22 from $20 at Scotiabank
2M ago
APLS
Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli
Premium
Ratings
Buy Rating for Apellis Pharmaceuticals Driven by FDA Approval and Promising Financial Projections for Empaveli
2M ago
APLS
Positive Outlook for Apellis Pharmaceuticals Following Empaveli Approval
PremiumRatings
Positive Outlook for Apellis Pharmaceuticals Following Empaveli Approval
2M ago
APLS
Cautious Optimism for Apellis Pharmaceuticals Amid Empaveli Approval and Market Challenges
PremiumRatings
Cautious Optimism for Apellis Pharmaceuticals Amid Empaveli Approval and Market Challenges
2M ago
APLS
Apellis price target raised to $46 from $41 at Citi
PremiumThe Fly
Apellis price target raised to $46 from $41 at Citi
2M ago
APLS
Apellis Pharmaceuticals: Buy Rating Driven by Empaveli’s Market Potential and Strong Growth Prospects
PremiumRatings
Apellis Pharmaceuticals: Buy Rating Driven by Empaveli’s Market Potential and Strong Growth Prospects
2M ago
APLS
Apellis Pharmaceuticals Receives Buy Rating Following Empaveli’s FDA Approval and Market Potential
PremiumRatingsApellis Pharmaceuticals Receives Buy Rating Following Empaveli’s FDA Approval and Market Potential
2M ago
APLS
FDA approves Apellis’ Empaveli for treatment of C3 glomerulopathy
Premium
The Fly
FDA approves Apellis’ Empaveli for treatment of C3 glomerulopathy
2M ago
APLS
Apellis Pharmaceuticals trading halted, news pending
Premium
The Fly
Apellis Pharmaceuticals trading halted, news pending
2M ago
APLS

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >